





JOINT TRANSNATIONAL CALL 2017: "Translational Research on Rare Cancers"

PARTNER REQUEST/COLLABORATION OFFER

If you would like to have your profile published on the TRANSCAN-2 website, "Looking for a research partner" webpage, please fill out this form and send it to 

If you have any questions about this form, please do not hesitate to contact us at 

Note: Fields marked with a * are mandatory

| Contact Information | |
|----------------------------|---|
| First name * | Virginia |
| Last name * | Brancato |
| Position * | Assistant Researcher |
| Telephone number | |
| E-mail address* | Virginia.brancato@dep.uminho.it |
| Website address | https://3bs.uminho.pt/ |
| Institution/Organisation * | University of Minho |
| Department* | 3B's Research Group - Biomaterials, Biodegradables and Biomimetics |
| Street | |
| Postal Code / City * | 4805-017 |
| Country * | Portugal |

*I agree with the publication of my contact data and of this form on the TRANSCAN-2 Website:

YES



SEARCH FOR A COLLABORATOR

IF YOU ARE LOOKING FOR A PARTNER IN YOUR SUGGESTED PROPOSAL, PLEASE SPECIFY ALSO THE NEEDED EXPERTISE

Project proposal

Project title (draft): A cholangiocarcinoma bioengineered model for drug screening

Short description of the project in preparation and of the consortium; description of the areas of expertise needed (Max. 2000 words):

The aim of this project is to development and exploitation of translational research platforms a patient-derived bioengineered tumor model to study drug responses/resistance and toxicity, and perform drug screens or repurpose approved anticancer drugs. Three-dimensional (3D) bioengineered cultures obtained from cholangiocarcinoma patients are able to mimic key properties of the original cancers. 3D cholangiocarcinoma models will be developed by using naturally derived matrices to support the growth of cell lines and patient derived cells, copycatting the spatial architecture of the cells and maintaining the cells heterotypicity (cancer, stromal, endothelial cells) naturally present in the tumor microenvironment. Researchers will have the opportunity to detect genetic, epigenetic or protein expression changes associated with drug sensitivity in order to define novel target molecules that could improve clinical outcomes in cancer patients. The consortium will strengthen the efforts to fabricate cholangiocarcinoma bioengineered tumor models to test conventional drugs currently approved for cholangiocarcinoma treatment as well as novel combination of drugs in order to make cholangiocarcinoma a more treatable disease.

REQUIRED EXPERTISES

-hospital or clinical partners with strong expertise in hepatocarcinoma and cholangiocarcinoma to provide biological specimens for the fabrication of the 3D ACC model.

3B's group has a strong background in management of European proposal so it will be the coordinator of the proposal.